Acute Exacerbation of Idiopathic Pulmonary Fibrosis with Lung Cancer: A Comparative Analysis of the Incidence, Survival Rate, and CT Findings with the Patients without Lung Cancer

Purpose To compare the incidence, survival rate, and CT findings of acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) between patients with and without lung cancer. Materials and MethodsFrom June 2004 to July 2018, 89 consecutive patients diagnosed with IPF were included.Among them, 26 patients had IPF with lung cancer (IPF-LCA), and 63 patients had IPF alone.The clinical characteristics and CT findings associated with IPF, lung cancer, and AE were reviewed.Surgery and chemotherapy were performed for 6 and 23 cases of lung cancer, respectively, as the first-or second-line anticancer treatment.The overall survival, CT findings, disease-free period before AE, and duration from the onset of AE to death were compared. ResultsThe incidence of AE was 61.5% in the IPF-LCA group and 58.7% in the IPF group (p = 0.806).The mean overall survival in the IPF-LCA and IPF groups were 16.8 and 83.0 months, respectively (p < 0.001).The mean durations from the start of the lung cancer treatment to the onset of AE were 16.0 and 4.6 months in cases of surgical treatment and chemotherapy, respectively.In comparison of death from AE, the survival rate was significantly lower in the IPF-LCA group than in the IPF group (p = 0.008).In the CT findings associated with AE, the IPF-LCA group tended to have a peribronchial (p < 0.001) or asymmetric distribution (p = 0.016).